CardioExchange Archive

July 11th, 2014

Do FFR and IVUS Feed the Elephant?

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hillis wonder whether the debate about the role of FFR and IVUS in patient selection for PCI is a red herring in the larger issue of revascularization in patients with stable CAD.

---

June 4th, 2014

Transcatheter Mitral Valve Programs: No Volume Data

Richard A. Lange, MD, MBA and L. David Hillis, MD

The Society for Cardiac Angiography and Interventions (SCAI), the American Association for Thoracic Surgery (AATS), the American College of Cardiology (ACC), and the Society of Thoracic Surgeons (STS) recently joined together to provide recommendations for institutions that are considering starting and/or maintaining a transcatheter mitral valve (MV) program. Unlike PCI, for which abundant data show a […]

---

November 18th, 2013

What’s the Moral from CORAL?

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hills ask, “Should we stop screening for renal artery stenosis?”

---

October 31st, 2013

Does OPTIMIZE Reveal the Optimal DAPT Time Frame?

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hillis pose several important questions triggered by the OPTIMIZE findings.

---

October 15th, 2013

Questions Remain About George W Bush’s Stent

L. David Hillis, MD

The National Journal reported yesterday that “George W. Bush’s recent heart problems were far more dangerous than generally believed — potentially life-threatening, in fact.” The Journal cited “an authoritative source”: “He was more than 95% occluded. With a blockage like that in a main artery you’re supposed to die. He was pretty lucky they caught it.” On the Nightly News” […]

---

September 20th, 2013

My Stent Is Better Than Your Stent

Richard A. Lange, MD, MBA and L. David Hillis, MD

Interventionalists have many choices when it comes to coronary stents. Rick Lange and David Hillis want to know: “How do you decide which stent to use?”

---

September 13th, 2013

Should We Treat Nonculprit Lesions During PCI for STEMI?

David S Wald, MA MD FRCP, Richard A. Lange, MD, MBA and L. David Hillis, MD

CardioExchange’s Rick Lange and David Hillis interview David Wald about his group’s recently published findings from the PRAMI trial of “preventive” PCI in STEMI patients. Based on results of previous nonrandomized, observational studies, stenting non-infarct coronary stenoses during primary PCI has been discouraged. The Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial in 465 STEMI patients assessed whether […]

---

September 1st, 2013

Inside the ACCOAST Trial of Pretreatment Prasugrel

Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD

Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.

---

August 28th, 2013

Platelet Reactivity Testing: Do You or Don’t You?

Richard A. Lange, MD, MBA and L. David Hillis, MD

In light of recent findings from the ADEPT DES study, Richard Lange and David Hillis want to know: Do you test PCI patients for platelet reactivity, and if so, why? React to reactivity in our latest poll.

---

March 14th, 2013

Fibrinolysis Now or Primary PCI Later?

Frans Van de Werf, MD,PhD, Richard A. Lange, MD, MBA and L. David Hillis, MD

CardioExchange’s Rick Lange and David Hillis ask Frans Van de Werf, principal investigator for the STREAM study, about his study group’s findings and their implications for clinical practice. THE STUDY In the STREAM trial, investigators compared two treatment strategies in STEMI patients presenting early after symptom onset who were unable to undergo primary PCI within 1 hour: […]

---